• News
  • RPG Group invests in Rs 4 crore in e-pharmacy MedsOnWay
This story is from November 7, 2017

RPG Group invests in Rs 4 crore in e-pharmacy MedsOnWay

The investment is part of RPG Group’s strategy to use RPG Ventures to incubate and build new businesses.
RPG Group invests in Rs 4 crore in e-pharmacy MedsOnWay
RPG Ventures, earlier this year, invested $1 million in Seniority - an online portal that sells elderly care products to senior citizens.
(This story originally appeared in on Nov 6, 2017)
MUMBAI: RPG Ventures, the venture capitalist arm of RPG Group has invested $600,000 (about Rs. 4 crore) in MedsOnWay, a chronic focused e-pharmacy.
The investment is part of RPG Group’s strategy to use RPG Ventures to incubate and build new businesses.
Medsonway is clocking a 15% month on month growth in revenues and orders over the course of the year, RPG Ventures stated.
At 250 orders per day and having served over 25,000 customers, Medsonway now sells more chronic medicines than leading pharmacy chains in the Pune market.
"Chronic medicines represent a Rs 30,000-crore market opportunity. With increasing incidence of lifestyle diseases in the country, this market is expected to maintain its growth rate and become the largest component the Indian pharma sector," stated RPG Ventures in a statement. "Subscription-based e-pharmacies are well positioned to cater to this growing market as the customer lifetime value for is high due to the long term nature of medication and high average order value."
RPG Ventures, earlier this year, invested $1 million in Seniority - an online portal that sells elderly care products to senior citizens. It is building a portfolio of startups around healthcare, cyber security, medical devices and artificial intelligence. It has invested $1 million each in some of these startups already.
author
About the Author
Megha Mandavia

I write on Internet businesses, social media companies, and their intersection with policy, politics and culture. Social media’s influence on online speech, political discourse and the society at large fascinates me. In my previous stints at the Economic Times, I have reported on boardroom battles, corporate governance and business strategy. In 2018, I won the University of Chicago's business journalism fellowship where I learnt about technology monopolies and their growing clout in the world. When not writing, I obsess about the unread books on my bookshelf.

End of Article
FOLLOW US ON SOCIAL MEDIA